Table 3.

Antileishmanial activity of AG, AGnp, and standard antileishmanial agents against L. donovani

Activity (IC50 ± SD or CC50) in μM concentrations
Drug tested	Axenic amastigote (IC50 ± SD)	Amastigote in macrophage (IC50 ± SD)	Cytotoxicity assay (CC50)
Formulation A	64 ± 8*	54 ± 5*	>1.2 × 103
Formulation B	36 ± 4*	28 ± 2*	>2 × 103
Formulation C	76 ± 6*	62 ± 8*	>1.8 × 103
Andrographolide	160 ± 26	141 ± 21	>103
Stibogluconate	410 ± 60*	246 ± 37**	>2.4 × 103
Amphotericin B	0.2 ± 0.1*	0.15 ± 0.1*	>13

Notes: Results expressed as mean ± SD (n = 3);

^*P < 0.01 significant difference compared with AG;

^**P < 0.05 no significant difference compared with AG.

Abbreviations: AG, andrographolide; AGnp, andrographolide nanoparticles; IC₅₀, inhibitory concentration 50%; CC₅₀, cytotoxicity concentration 50%.